newsfilter
← Earnings
Earnings Releases·

Gain Therapeutics — Third Quarter 2026 Earnings Summary

Gain Therapeutics reported a net loss of $3.2 million for the third quarter of 2026, with research and development expenses decreasing to $1.4 million. The company presented long-term data from its Phase 1b trial of rexaceract in Parkinson's disease, showing no motor symptom progression after 12 months of treatment. Cash and cash equivalents stood at $11.7 million as of September 30, 2026, down from $20.8 million at the end of 2025. The company expects to initiate a Phase 2 clinical trial for rexaceract in the first quarter of 2027 and plans to advance its second candidate, GT-04686, into clinical development in the fourth quarter of 2026.

Company
GAIN THERAPEUTICS INC
Sector
Healthcare
Industry
Biotechnology